Save on Deucravacitinib with Coupons, Discounts & Savings Programs

Deucravacitinib is available as a 6 mg oral tablet.

Deucravacitinib is a tyrosine kinase 2 inhibitor that is used to treat moderate-to-severe plaque psoriasis.

Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor. It targets an enzyme (protein) in the Janus kinase (JAK) family called tyrosine kinase 2. This protein normally causes inflammation in the body. Although it’s not completely clear how Deucravacitinib works to help treat plaque psoriasis, it’s thought to lower inflammation by blocking TYK2.

Deucravacitinib is typically taken as 6 mg by mouth once daily.

Deucravacitinib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Deucravacitinib:

• Upper respiratory infections
• Herpes simplex infection (e.g., cold sores, genital herpes)
• Mouth ulcers
• Swollen hair follicles
• Acne

Serious side effects are rare with Deucravacitinib. Contact your healthcare provider immediately if you experience any of the following.

• Severe allergic reaction: rash, trouble breathing, feeling faint, swelling of the face or throat
• Serious infection: fever, weakness, chills, trouble breathing, cough, diarrhea, stomach pain, burning when you urinate, urinating more or less often
• Severe muscle damage (rhabdomyolysis): dark brown urine, severe muscle weakness or pain, fever, tiredness
• Liver damage: nausea, stomach pain, yellowing of the skin or whites of the eyes
• Cancer

There are no major drug interactions listed for Deucravacitinib. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

It is not known if Deucravacitinib can harm your unborn baby.
Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.

• Sotyktu